期刊文献+

丙酸氟替卡松吸入气雾剂联合沙美特罗替卡松粉吸入剂治疗哮喘的临床疗效 被引量:1

Clinical efficacy of fluticasone propionate powder inhalation combined with salmeterol fluticasone powder inhalation in the treatment of asthma
原文传递
导出
摘要 目的 观察丙酸氟替卡松吸入气雾剂联合沙美特罗替卡松粉吸入剂治疗哮喘的临床疗效。方法 选取2019年10月—2021年10月郴州市第三人民医院北院收治的哮喘患者106例,按照随机对照原则分为吸入型糖皮质激素(ICS)组(n=53例)和联合组(n=53例)。ICS组予以丙酸氟替卡松吸入气雾剂,联合组予以丙酸氟替卡松吸入气雾剂联合沙美特罗替卡松粉吸入剂。2组疗程均为1个月。比较2组临床疗效,治疗前及治疗1个月后肺功能指标[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、呼气流量峰值(PEF)]、白三烯C4(LTC4)、呼出气一氧化氮(FeNO)、炎性因子[C反应蛋白(CRP)、降钙素原(PCT)],不良反应。结果 联合组总有效率为94.34%,高于ICS组的77.36%(χ^(2)=8.230,P=0.004)。治疗1个月后,2组FEV_(1)、FVC、PEF较治疗前升高,LTC4、FeNO、CRP、PCT水平较治疗前降低,且联合组FEV_(1)、FVC、PEF高于ICS组,LTC4、FeNO、CRP、PCT水平低于ICS组(P<0.01)。2组不良反应总发生率比较,差异无统计学意义(P=1.000)。结论 哮喘患者应用丙酸氟替卡松吸入气雾剂联合沙美特罗替卡松粉吸入剂的疗效较好,可明显改善其肺功能,降低炎症损伤,且不良反应较少。 Objective To observe the clinical efficacy of fluticasone propionate powder inhalation combined with salmeterol fluticasone powder inhalation in the treatment of asthma. Methods A total of 106 cases of patients with asthma were selected from October 2019 to October 2021 in Chenzhou Third People′s Hospital North Yard, which were divided into ICS group(n=53 cases) and combined group(n=53 cases) according to the principle of random control. The ICS group was given fluticasone propionate powder inhalation, and the combined group was given fluticasone propionate powder inhalation combined with salmeterol fluticasone powder inhalation. The course of treatment in both groups was 1 month. Clinical efficacy, pulmonary function indexes(FEV_(1), FVC, PEF), LTC4, FeNO, inflammatory factors(CRP, PCT) before and after 1 month of treatment, incidence adverse reactions were compared between the two groups. Results The total effective rate of the combined group was 94.34%, which was higher than 77.36% of the ICS group(χ^(2)=8.230, P=0.004). After 1 month of treatment, FEV_(1), FVC and PEF in the two groups increased, while LTC4, FeNO, CRP and PCT levels decreased, FEV_(1), FVC and PEF in the combined group were higher than those in the ICS group, while LTC4, FeNO, CRP and PCT levels were lower than those in the ICS group(P<0.01). There was no significant difference in the total incidence of adverse reactions between the two groups(P=1.000). Conclusion The curative effect of fluticasone propionate powder inhalation combined with salmeterol fluticasone powder inhalation is better for asthma patients, it can obviously improve the lung function, reduce the inflammatory injury, and with fewer adverse reactions.
作者 张建 李茉莉 周辉 ZHANG Jian;LI Moli;ZHOU Hui(Department of Respiratory Critical Care Medicine,Chenzhou Third People′s Hospital North Yard,Chenzhou 423001,China;不详)
出处 《临床合理用药杂志》 2023年第6期26-28,32,共4页 Chinese Journal of Clinical Rational Drug Use
关键词 哮喘 沙美特罗替卡松粉吸入剂 丙酸氟替卡松吸入气雾剂 治疗结果 肺功能 炎性因子 Asthma Salmeterol fluticasone powder inhalation Fluticasone propionate powder inhalation Treatment outcome Lung function Inflammatory factors
  • 相关文献

参考文献10

二级参考文献72

共引文献272

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部